Description
The Market and Potential for CRISPR/Cas9 Gene Editing
This report consolidates the information and trends and provides reliable market estimates for CRISPR technology to 2023. As part of the report’s coverage, it provides the following:
- Market Size and Forecast for CRISPR/Cas9 Gene Editing, 2017-2023
- The Market for CRISPR/Cas9 by Region (N. Amer. EU, ROW), 2017-2023 Analysis of Growth Trend by Region
- Market by Application (Cancer Research, Non-Cancer Disease Research, Cancer Diagnostics, Infection Diagnostics, Plant, Food, Biofuel, Drug Discovery, Drug Development, Other)
- Growth Trend, U.S.
- Growth Trend, Outside U.S.
- Market by End User (Hospitals, University, Medical Research Institute, Government), 2017
- Market by End User (Hospitals, University, Medical Research Institute, Government), 2023
- Recent Technology and Market Developments and Medical Studies
- Partnerships Involving CRISPR Gene Editing
Companies in the Market and Partnerships in Gene Editing
In 2018, more than 30 players participate in this market, from large multinational corporations to small, niche life sciences companies. Key players include Agilent, MilliporeSigma, GE Healthcare Dharmcon, GeneScript, Horizon Discovery Group, OriGene, ThermoFisher Scientific, Transposagen, and ToolGen. These companies develop and commercialize various products and services for each of the major gene editing technologies.
The nature of CRISPR’s complex technology requires partnerships between the developers of the technology and the healthcare concerns with distribution strength and a broader product base. These developments are outlined in the report.
Recent Lawsuit and Industry Risk Analysis
Currently, one of the more significant factors in commercializing CRISPR-Cas9 as a viable therapeutic tool is the current legal battles surrounding the technology. The issue started when both the University of California, Berkeley (UCB) and the Broad Institute of MIT (the Broad) both filed patents related to this technology. While there’s been some resolution, the report provides an analysis of developments.
Table of Contents
1: EXECUTIVE SUMMARY
OVERVIEW
gRNA
Enzyme
Figure 1-1: PubMed References for “CRISPR” 2011-est. 2018
INDUSTRY RISK ANALYSIS – PATENT LANDSCAPE
Impact of the Initial Ruling
How Things Stand Now in the US
How Things Stand in Europe
Conclusions
OTHER RECENT CRISPR/CAS9 DEVELOPMENTS
NIH GRANTS FOR CRISPR PROJECTS
Figure 1-2: Grants for CRISPR-based Projects, NIH
CRISPR/Cas9 NIH Projects by End User
Figure 1-3: NIH Project Grant Recipients by type
THE MARKET FOR CRISPR EQUIPMENT AND SUPPLIES
Figure 1-4: Market for CRISPR Technologies, 2017-2023
Market by Geography
Table 1-1: CRISPR Gene Editing Market, 2017-2023
TRENDS IN GENE EDITING
Table 1-2: Significant Trends in the Market for Gene Editing Technologies, 2016
SIGNIFICANT PARTNERSHIPS IN GENE EDITING
Table 1-3: Selected Gene Editing Partnerships
2: CRISPR PRODUCTS AND TRENDS
OVERVIEW
Advantages and Disadvantages of CRISPR
Table 2-1 Advantages and Limitations of CRISPR-Cas9 Technology in Gene Editing, 2016
RECENT APPLICATIONS AND DEVELOPMENTS
Malaria Control
Gene-Edited Sheep for Regenerative Medicine
Improved Vaccine Creation
Obesity Control
Epstein-Barr Virus
Protein Coding
Improving Chinese Herbs
Identifying Drug Resistance Mutations
Immune Therapies for Cancer
Enabling Bacterial Cell Factories
Muscular Dystrophy
“Piggy Bac” Process for Stem Cells
Clarity on Salmonella Ser. Kentucky
Better Human Disease Models
Editing of Bread Wheat
Cancer Cell Phagocytosis
Refining Gene Editing
COMPANIES IN CRISPR GENE EDITING
Table 2-2: Products on the Market
COMMERCIAL APPLICATIONS OF GENE EDITING TECHNOLOGIES
USING CRISPR FOR DIAGNOSTICS
USING CRISPR FOR HUMAN THERAPEUTICS
Table 2-3: Gene Editing-Based Therapies
Selected CRISPR-Cas9 Gene Editing Products
Table 2-4: Commercial Gene Editing Products on the Market
CRISPR COMPANIES
Agilent
Allele Biotechnology
Applied Biological Materials
Dharmacon
DNA 2.0
GeneCopoeia
GenScript
Horizon Discovery Group, Plc
Integrated DNA Technologies
MilliporeSigma
OriGene
PNA Bio
Santa Cruz Biotechnology
System BioSciences
Takara Bio (Clontech)
ThermoFisher Scientific
ToolGen
TriLink Biotechnology
Table 2-5 Significant Trends in the Market for Gene Editing Technologies, 2018
3: GENE EDITING MARKET ANALYSIS
COMPETITIVE ANALYSIS
THE MARKET FOR CRISPR EQUIPMENT AND SUPPLIES
Figure 3-1: Market for CRISPR Technologies, 2017-2023
Market by Geography
Table 3-1: CRISPR Gene Editing Market (N. Amer. EU, ROW), 2017-2023
GROWTH TREND
Figure 3-2: Growth Trend in the CRISPR Market, 2017-2022
Growth Trend in North America and Europe
Figure 3-3: Growth Trend in North America and Europe
Growth Trend in the Rest of the World
Figure 3-4: Growth Trend in the Rest of the World
MARKET BY APPLICATION
Figure 3-5: Market by Application (Cancer Research, Non-Cancer Disease Research, Cancer Diagnostics, Infection Diagnostics, Plant, Food, Biofuel, Drug Discovery, Drug Development, Other)
MARKET BY END USER
Figure 3-6 Market by End User (Hospitals, University, Medical Research Institute, Government), 2017
Figure 3-7 Market by End User (Hospitals, University, Medical Research Institute, Government), 2023
4: GENE EDITING PARTNERSHIPS
CARIBOU BIOSCIENCES, INC.
SANGAMO BIOSCIENCES
Shire International
Pfizer Inc.
Bioverativ Inc.
CRISPR THERAPEUTICS
Bayer
Vertex Pharmaceuticals
MaSTherCell
Neon Therapeutics
Massachusetts General Hospital Cancer Center
CureVac AG
EDITAS MEDICINE
Allergan plc
Adverum
Juno Therapeutics
INTELLIA THERAPEUTICS
Regeneron Pharmaceuticals
Novartis
PRECISION BIOSCIENCES
BLUEBIRD BIOTECHNOLOGIES
CHRISTIANA CARE’S GENE EDITING INSTITUTE
The Wistar Institute
NovellusDx
Analytical Biological Services
CASEBIA THERAPEUTICS
CRISPR Therapeutics and MaxCyte
Seattle Children’s Research
CRISPR Therapeutics and CureVac AG
SYNTHEGO
Thermo Fisher Scientific
SAREPTA THERAPEUTICS
HOMOLOGY MEDICINES
GENSCRIPT
CELLECTIS, INC.
Pfizer
Servier
MERCK
TWIST BIOSCIENCE, DESKTOP GENETICS
ASTRAZENECA
The Wellcome Trust Sanger Institute
The Innovative Genomics Initiative
Thermo Fisher Scientific
Broad Institute / Whitehead Institute
Table 4-1: Selected Gene Editing Partnerships
INCREASING INVESTMENTS AND FUNDING IN GENE EDITING AREA TO AUGMENT MARKET REVENUES
Exonics Therapeutics
Synthego
Homology Medicines
Editas Medicine
Intellia Therapeutics
CRISPR Therapeutics
Poseida Therapeutics
Recombinetics
Table 4-2: Selected Gene Editing Investments
